52P Modified FOLFIRINOX versus CISGEM as first-line chemotherapy for advanced biliary tract cancer: Results of AMEBICA PRODIGE 38 randomized phase II trial.
Saved in:
| Title: | 52P Modified FOLFIRINOX versus CISGEM as first-line chemotherapy for advanced biliary tract cancer: Results of AMEBICA PRODIGE 38 randomized phase II trial. |
|---|---|
| Authors: | Phelip, J.M.1 (AUTHOR), Desrame, J.2 (AUTHOR), Edeline, J.3 (AUTHOR), Barbier, E.4 (AUTHOR), Terrebonne, E.5 (AUTHOR), Michel, P.6 (AUTHOR), Perrier, H.7 (AUTHOR), Dahan, L.8 (AUTHOR), Bourgeois, V.9 (AUTHOR), Khemissa Akouz, F.10 (AUTHOR), Soularue, E.11 (AUTHOR), Lebrun, V. Ly12 (AUTHOR), Molin, Y.13 (AUTHOR), Lecomte, T.14 (AUTHOR), Ghiringhelli, F.15 (AUTHOR), Coriat, R.16 (AUTHOR), Louafi, S.17 (AUTHOR), Neuzillet, C.18 (AUTHOR), Manfredi, S.19 (AUTHOR), Malka, D.20 (AUTHOR) |
| Source: | Annals of Oncology. 2020 Supplement 4, Vol. 31, pS260-S261. 2p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2020.08.030 |
